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Yttrium-90 radioembolization (
90 Y RE) is a contemporary transcatheter locoregional therapy for primary and secondary hepatic malignancies that is commonly utilized in modern Interventional Radiology (IR) practice. 1 Unlike other targeted endovascular therapies, such as transarterial chemoembolization (TACE) and transarterial embolization (TAE), the current standard of care protocol for 90 Y RE treatment of liver tumors involves a two-stage treatment process consisting of a planning arteriography procedure followed by the therapeutic 90 Y RE, typically performed 1 to 2 weeks later. The diagnostic planning procedure has threefold intent: (1) to delineate hepatic and tumor vascular anatomy relevant to 90 Y microsphere dosimetry and administration; (2) to identify and possibly embolize extrahepatic vessels at risk for nontarget microsphere deposition; and (3) to quantify the degree of hepatopulmonary shunting using technetium-99m macroaggregated albumin ( 99m Tc-MAA) scanning. 2 Given the multifactorial basis for performance of mapping arteriography, and despite some literature guidelines outlining procedure methodology, 3, 4 this procedure is often technically challenging, labor intensive, and time consuming. This article aims to present a simple overview of a single operator's technical approach to planning arteriography performed prior to 90 Y RE-including tips, tricks, and pitfalls-based on experience gained in having performed hundreds of hepatic arteriography procedures. Technical details of 90 Y RE dosimetry and microsphere administration are beyond the scope of the current topic, and will not be discussed.
Preprocedure Considerations
As with all IR locoregional liver therapies, 90 Y RE treatment at the author's institution is preceded by an IR clinic consultation. The intent of the outpatient encounter is to obtain patient historical information; to perform a baseline physical examination; to identify any potential procedural contraindications; and to review the patient's diagnosis and treatment plan, as well as clinical outcome goals and expectations with him/her. Relevant contraindications to 90 Y RE are well described, 5 but particular attention is paid to baseline performance status and serum bilirubin level, which, if elevated, may preclude treatment. While renal insufficiency does not represent an absolute procedural contraindication, the author prefers to pursue a single-session therapy such as transarterial chemoembolization as opposed to two-stage 90 Y RE to limit iodinated contrast volume administered to patients with kidney dysfunction. In terms of other preprocedure needs, all patients should have an up-to-date, highquality contrast-enhanced triple-phase (liver protocol) computed tomography (CT) or magnetic resonance (MR) imaging scan for baseline tumor staging, ideally performed within a couple of weeks of initial therapy. On the day of the arteriography procedure, prophylactic antibiotics are typically not required.
General Procedure Approach
The ternary objective of the planning arteriogram prior to 90 Y RE warrants IR operators to consider the optimal chronological order in which to undertake the required tasks. Given that injection of 99m Tc-MAA is always the last step of a planning arteriogram, this decision revolves around whether to perform complete diagnostic arteriography first and embolization second, or vice versa. The author's preferred approach is that of diagnostic arteriography followed by nontarget vessel embolization. This sequence is favored based on multiple considerations. First, the need for embolization of nontarget vessels such as the gastroduodenal artery (GDA) and right gastric artery (RGA) may not be known until the planned 90 Y administration site is clarified by hepatic arteriography. As such, embolization pursued at the procedure outset may result in unnecessary vessel occlusion. Second, diagnostic arteriography, including delineation of tumor vascular supply and identification of prospective 90 Y administration sites, requires careful attention by the operating IR physician. If technically challenging, performance of nontarget vessel embolization first may result in operator fatigue that might undermine the allotment of sufficient concentration. Third, performing hepatic arteriography first allows dedication of ample iodinated contrast volume to the diagnostic component of the procedure and helps prevent over usage of iodinated contrast material by avoiding initial over utilization during the embolization component of the procedure.
Step-by-Step Procedural Technique
Getting Started
Hepatic arterial mapping procedures with 99m Tc-MAA administration are performed in the IR suite using intravenous moderate sedation. General anesthesia is rarely required and is limited to cases of patient preference or tolerance to narcotic medications commonly used for sedation and analgesia. To begin, routine arterial access is gained via the common femoral artery using sonographic guidance and a 21-gauge needle (Micropuncture Introducer Set; Cook Medical, Bloomington, IN). Vascular access is dilated to a 5F sheath (Pinnacle; Terumo, Somerset, NJ). While not used at the author's institution, the radial artery represents an alternative vascular access site.
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Diagnostic Arteriography
As previously noted, the aim of diagnostic arteriography performed during 90 Y RE planning is to delineate hepatic vascular anatomy relevant to microsphere dosimetry and administration, and to identify extrahepatic vessels at risk for nontarget microsphere deposition. At the conclusion of the diagnostic component of the procedure, the IR operator should have a firm understanding of where tumor vascular supply is derived from, which vascular territories and vessels require treatment, the flow characteristics in these vascular beds, and the likelihood for nontarget microsphere deposition based on likely 90 Y administration location. This is accomplished by systematic catheter interrogation of the celiac and hepatic vasculature.
To begin, celiac arteriography is performed using a 5F catheter such as SOS Omni Selective (AngioDynamics; Queensbury, NY), SIM 1 (Cook Medical), or C2 (Cook Medical) catheter. In the author's opinion, performance of an aortogram or superior mesenteric arteriogram is typically not necessary (in the absence of known variant vascular anatomy), as high-quality preprocedure cross-sectional imaging with CT or MR imaging routinely provides anatomic information about vascular anatomy-including aberrant vasculature -and portal venous patency. Furthermore, the iodinated contrast volume saved by deferring aortography and superior mesenteric arteriography can be applied to performing more hepatic arteriograms or undertaking more arteriography during embolization, if necessary. Nonetheless, celiac imaging carried through the venous phase may depict splenoportal patency via a delayed splenoportogram.
Hepatic arteriography is performed after placement of a coaxial 3F microcatheter such as a Renegade Hi-Flo (Boston Scientific, Natick, MA), or after exchange for a 4F catheter (Glidecath; Terumo). Use of a 4F catheter system can often improve arteriographic imaging and tumor visualization by providing higher iodinated contrast injection rate capability compared with most microcatheter systems, which may not be able to overcome very hyperdynamic hepatic arterial flow as is often seen in liver cirrhosis (►Fig. 1). When performing hepatic arteriography, it is of paramount importance to achieve adequate filling of injected vascular beds to ensure complete filling of all arteries to guarantee visualization of both tumor and any potential nontarget vessels that may require embolization. Complete hepatic arteriography typically includes selective common hepatic, proper hepatic, left hepatic, and right hepatic arteriography, as well as segmental arteriography and/or super selective arteriography performed at the discretion of the IR physician. Some extrahepatic vessels-such as the right inferior phrenic artery-may Planning Arteriography for Yttrium-90 Microsphere Radioembolization Gaba 429 on occasion require arteriographic interrogation, as these can contribute to parasitized blood flow to primary liver tumors. Typical iodinated contrast material injection rates used by the author for the celiac artery and hepatic or other branches relevant to 90 
Nontarget Vessel Embolization
The multitude of vessels at risk for potential nontarget microsphere deposition have been well described in the literature, and include the GDA, RGA, falciform artery (►Fig. 6), and cystic artery, among others. 4 The decision of whether to embolize a potential nontarget vessel can often be challenging. Early in an IR operator's 90 Y RE practice, it is probably prudent to occlude all potential nontarget vessels that can safely be embolized-most frequently the GDA and RGA-using metallic coils such as MicroNester coils (Cook Medical), to avoid radiation-induced ulcers and to ensure a high level of procedural safety during initial experience with this therapy. As one's knowhow expands and clinical practice matures, embolization of such extrahepatic vessels may not be considered mandatory if 90 Y RE can be performed at a safe distance from the vessel origin, per the judgment of the IR physician. 9 However, since arterial stasis is a risk factor for gastrointestinal ulceration, 10 embolization should be strongly considered when a high 90 Y microsphere load is to be used for therapy, as in the case of resin microspheres, or when small or low flow vascular territories are to be treated. In the author's practice, nontarget vessel embolization is typically performed when resin microspheres are to be used for treatment, when the prospective 90 Y administration site is close in proximity to the GDA or RGA, for all arterial variants arising from an intrahepatic artery (e.g., accessory gastric artery arising from left hepatic artery, ►Fig. 7), and prior to 
Embolization Technique
From a technical standpoint, embolization of a medium-sized vessel such as the GDA is generally straightforward. Most Planning Arteriography for Yttrium-90 Microsphere Radioembolization Gaba 431
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challenges in GDA embolization arise with placement of the last coil near the vessel origin from the common hepatic artery, where careless technique can result in coil migration. Tips to successful deployment of the last coil include use of the "anchor" technique (►Fig. 8) and use of a supporting 4F catheter advanced to the GDA origin to ensure avoidance of microcatheter recoil and dislodgment from the vessel during coil deployment (►Fig. 8). Detachable coils or vascular plug devices may also be useful in this circumstance, given the capacity for precise placement (►Fig. 9) and for potential removal if malpositioned. RGA embolization is often a source of frustration. An obvious key to successful embolization of this vessel is catheterization. To this end, the author always performs a Planning Arteriography for Yttrium-90 Microsphere Radioembolization Gaba 433
common hepatic arteriogram at full magnification to clearly identify the RGA origin (►Fig. 10), which assists with successful wire cannulation. Once catheterized, the author typically embolizes this vessel using 3-mm coils "unsheathed" from the microcatheter using a wire pusher, to avoid pushing the microcatheter out of the vessel during aggressive coil advancement. If the RGA cannot be catheterized primarily, retrograde catheterization and embolization via a left gastric artery to RGA arcade-if present-is a useful and well-described approach (►Fig. 11). If embolization of the RGA or another vessel is technically unsuccessful during the planning arteriogram procedure, the IR operator should remember that he/she will have a second opportunity to attempt the embolization at the time of 90 Y administration.
Another option is to use an antireflux catheter for 90 Y microsphere administration. Finally, the decision to push versus inject coils is usually at the discretion of the primary IR operator. The author's preference is to inject most coils and to reserve coil pushing to cases of small vessel (e.g., RGA) embolization and for last coil deployment near a vessel origin from a parent artery. While everyone performing mapping arteriography prior to 90 Y RE procedures will inevitably encounter a coil migration incident, the response to this mishap is important. While it is desirable to remove a migrated coil from a hepatic circulation for which treatment is desired, too much or careless manipulation can also result in injury such as vessel dissection. In the circumstance of coil migration into the hepatic circulation or even herniation of a coil into a parent vessel, the author will attempt to remove or retrieve the coil if a free end is available for capture (►Fig. 13, 14 In this scenario, complete occlusion of the branch vessel into which coil migration occurred may be used to develop collateral blood supply from other intrahepatic arteries to allow 90 Y administration (►Fig. 14); while not an ideal circumstance, this approach may be the most successful in some patients.
Special Considerations
As has been noted by others, 90 Y RE treatment of the left hepatic artery may be precarious, as this vessel more commonly harbors relevant anatomic variants compared with the right hepatic artery. Examples include a gastrohepatic trunk (►Fig. 15), as well as accessory gastric, esophageal, and phrenic (►Fig. 16) arteries that may go unrecognized and which may increase the risk for nontarget 90 Y delivery. Moreover, compared with the right hepatic artery, the left hepatic artery is typically smaller in caliber, has a shorter undivided segment that does not permit as distal microcatheter positioning, supplies a smaller liver volume, and possesses a less capacious vascular bed, all of which theoretically raise the risk for embolic stasis, reflux, and/or vascular saturation. With these considerations in mind, the author routinely pursues GDA and RGA embolization in the setting of unilateral left hepatic lobe 90 Y RE, knowing that the incidence of gastrointestinal ulceration is likely low when protective measures are applied. In cases of bilobar malignant disease, however, the author has occasionally adopted a treatment approach that omits left hepatic lobe 90 Y (and risk for gastrointestinal ulceration)
altogether and employs a locoregional strategy that potentially affords some practical, methodological, and logistical benefits. In cases of bilobar tumor, the author performs left Planning Arteriography for Yttrium-90 Microsphere Radioembolization Gaba 435
controlled and directly monitored manner at present (although some operators inject 90 Y resin particles as a suspension in iodinated contrast material). Furthermore, such treatment consolidation allows earlier completion of treatment cycle, as patients typically achieve whole liver therapy in 10 to 14 days over two procedures, as opposed to 5 to 6 weeks over three procedures for routine bilobar 90 Y therapy (in which planning arteriography is performed at time zero followed by treatment of one liver lobe 10-14 days later and the second liver lobe 1 month after that).
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Another potential theoretical benefit of this approach that may be exploited in research studies is the capability for within-patient comparison of locoregional treatment efficacy (chemoembolization vs. 90 Y RE), although such a comparison could be confounded by factors such as therapy lead time bias as well as differences in baseline tumor characteristics, such as size. While the author does not have a substantial enough patient cohort on which to report at this time, this approach has anecdotally been found by the author to provide an efficient means to treat bilobar liver tumor patients. As a final note, intrahepatic flow redistribution could also be used in the scenario described, with coil embolization of the left hepatic artery and whole liver treatment via the right hepatic artery.
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Hepatopulmonary shunt ratio is calculated using the following formula:
% LSF ¼ (total lung counts/total lung þ total liver counts) Â 100
Abdominal shunt fraction, defined as total extrahepatic abdominal counts/total extrahepatic abdominal þ total liver counts Â 100, is similarly calculated using ROIs drawn around the liver and extrahepatic abdomen. Tc-MAA scanning is vital to any IR with an interventional oncology practice. Although the procedure technique may vary between operators, with a spectrum of different individual, institutional, regional, and national practice patterns, a diligent approach of patient evaluation and arteriographic methodology enhances technical success and optimizes oncologic care for patients. 
